Summary
Merck & Co., Inc. (Merck) is a healthcare company, which focuses on the discovery, development, manufacture and commercialization of branded pharmaceuticals, biologic therapies, prescription and over-the-counter (OTC) medicines, vaccines, consumer care products and animal healthcare products. It offers prescription products for cardiovascular diseases, endocrine, immunological and infectious diseases, neurological, respiratory and urological diseases, ophthalmic conditions, cancer and women’s health. The company offers its products to wholesalers and retailers, hospitals, government agencies, managed health care providers and veterinarians. It has operations in North America, South America, Europe, the Middle East and Africa, and Asia Pacific. It is also known as MSD outside the US and Canada. Merck is headquartered in Kenilworth, New Jersey, the US.
Merck & Co., Inc. (MRK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 16
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 17
Merck & Co., Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 18
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 19
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 20
Merck & Co., Inc., Medical Devices Deals, 2010 to YTD 2016 22
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 23
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deal Details 42
Asset Purchase 42
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 42
Merck Reacquires Cherokee Chemical Manufacturing Plant From PRWT Services 43
Merck Sharp & Dohme Acquires Dengue Fever Vaccine Research Unit From Hawaii Biotech 44
Venture Financing 45
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 45
RaNA Therapeutics Raises USD55 Million in series B Financing 47
Gladius Pharma Raises USD3.3 Million in Series A Financing 49
NGM Biopharma Raises USD106 Million in Series E Financing 50
EnGene Raises USD11 Million in Series B Venture Financing 51
OsteoQC Raises Funds in Venture Financing 52
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 53
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 54
Aviir Raises US$20 Million In Venture Financing 56
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 58
Aviir Secures US$10 Million In Venture Financing 59
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 61
BeiGene Receives Investment From Merck Sharp & Dohme 63
SmartCells Raises US$4.1 Million In Series D Preferred Stock Financing 64
TPP Global Development Raises US$14.2 Million In Venture Financing 65
Partnerships 66
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 66
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 67
Merck and Sanofi Pasteur Plans to Terminate Joint Venture 68
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 69
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 70
Sun Pharma Terminates Joint Venture with MSD Pharma 71
ImmunoGen Enters into Research Agreement with Merck 72
Merck Enters into Agreement with AbCellera Biologics 73
Affimed Enters into Research Agreement with Merck 74
BioLineRx Enters into Agreement with Merck 75
Quartet Medicine Enters into Agreement with Merck 76
Complix Enters into Agreement with Merck 77
Eli Lilly Enters into Agreement with Merck 78
Merck Enters into Agreement with Akeso Biopharma 79
Amgen and Merck Enter into Agreement 80
Viralytics Enters into Agreement with Merck 81
GlaxoSmithKline Partners with Merck 82
Synthace Enters into Agreement with Merck 83
MacroGenics Enters into Agreement with Merck 84
Incyte Extends Partnership with Merck 85
Merck Enters into Agreement with OBI Pharma 86
Merck Enters into Agreement with DNAtrix 87
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 88
Immune Design Enters into Clinical Collaboration Agreement with Merck 89
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 90
Merck Sharp & Dohme Expands its Agreement with NanoString Technologies 91
PeptiDream Enters into Peptide Discovery Agreement with Merck 92
Organovo Enters into Research Agreement with Merck Sharp & Dohme 93
Astellas Pharma to Enter into Agreement with MSD 94
Syndax Pharma Enters into Agreement with Merck 95
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 96
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 97
Laboratoires Merck Sharp Terminates Joint Venture with Simcere Pharma 99
Merck Expands Agreement with Eli Lilly 100
Kyorin Pharma Enters into Co-Marketing Agreement with MSD 101
Bind Therapeutics Enters into R&D Agreement with Merck 102
Advaxis Enters into Agreement with Merck 103
Endocyte Terminates Co-Development Agreement with Merck for vintafolide 104
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 105
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 107
Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 109
Dako Enters Into Co-Development Agreement With Merck 110
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 111
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 113
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 115
Abide Therapeutics Enters Into Co-Development Agreement With Merck 116
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 117
Ra Pharma Enters Into Agreement With Merck To Develop Cyclomimetics 119
Merck And Samsung Bioepis Enter Biosimilars Development Agreement 120
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 121
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 122
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 123
ActoGeniX Enters Into Research Agreement With Merck 124
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 125
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 126
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 127
Redbiotec Extends Drug Discovery Agreement With Merck 129
Merck Forms Joint Venture With Supera Farma Laboratorios 130
MSD Enters Into Distribution Agreement With Julphar 131
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 132
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 134
Chongqing Zhifei Biological Products Extends Co-Marketing Agreement With Merck For RotaTeq 135
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 136
Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 137
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 139
Takeda Pharma International Terminates Co-Promotion Agreement With Merck For Daxas 140
Ezose Sciences Enters Into Co-Development Agreement With Merck 141
Vaccine & Gene Therapy Institute Enters Research Agreement With Merck 142
Redbiotec Enters Into Drug Discovery Agreement With Merck 143
Merck Enters Into Co-Development Agreement With Beijing Genomics Institute 144
Merck Enters Into Co-Development Agreement With Serum Institute of India 145
Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 147
Merck Enters Into Co-Promotion Agreement With Daewoong Pharma For Vytorin 149
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 150
MSD In India Enters Into Co-Marketing Agreement With Sun Pharma 152
Merck Amends Distribution Agreement With Johnson & Johnson 154
Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma 156
TPP Global Development Enters Into Agreement With University of Aberdeen 158
ARIAD Announces Co-Promotion Agreement With Merck 159
Lycera Enters Into Research Agreement With Merck 160
Merck & Co. Terminates Co-Development Agreement With Galapagos For Inflammatory Diseases 162
Merck & Co. Terminates Co-Development Agreement With Galapagos 163
Merck Enters Into An Agreement With PAREXEL International 164
Ranbaxy Labs Terminates Co-Development Agreement With Merck 165
H Lundbeck Enters Into Collaboration With Merck For SYCREST 166
BioRelix Enters Into Research Collaboration With A Subsidiary Of Merck 168
NicOx Expands Research Collaboration With Merck & Co 169
Karo Bio Terminates Its Collaboration With Merck & Co For MK-6913 170
Adcock Ingram Holdings Expands Its Distribution Agreement With Merck 171
TPP Global Development Enters Into Collaboration Agreement With The University Of Edinburgh 172
Alectos Therapeutics Enters Into Research Collaboration With Merck & Co 173
Merck & Co Enters Into Co-Marketing Agreement With Sinopharm Group 174
Merck Sharp & Dohme Signs Letter Of Intent With Sinopharm Group 175
Adcock Ingram Enters Into Co-Promotion And Distribution Agreement With Merck 176
Pharmasset Plans Co-Development Agreement For PSI-7977 178
National Taiwan University Hospital Enters Into Collaboration With Merck Sharp 180
Nycomed Enters Into Co-Marketing Agreement With Merck 181
Nycomed Enters Into Co-Promotion Agreement With Merck 183
Laboratorios Farmaceuticos Enters Into Co-Marketing Agreement With Merck & Co 185
University of Pittsburgh Partners With Battelle, IBM And Merck 186
Banyu Pharma Enters Into Co-Promotion Agreement With Santen Pharma 188
Evotec Extends Research Agreement With Cubist Pharma 189
Eli Lilly, Merck And Pfizer Form Joint Venture 190
AnaptysBio Enters Into Collaboration Agreement With Merck 192
Envoy Therapeutics Enters Into Research Agreement With Merck & Co. 193
Licensing Agreements 194
Merck Enters into Licensing Agreement with Harvard University 194
Merck Enters into Licensing Agreement with AureoGen Biosciences 195
Merck Enters into Licensing Agreement with Cancer Research Technology 196
Adimab Enters into Licensing Agreement with Merck 197
Merck Enters into Licensing Agreement with Selvita 198
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 199
Allergan Enters into Licensing Agreement with Merck 201
Merck Extends Licensing Agreement with Agenus 202
Arvinas Enters into Licensing Agreement with Merck 203
Merck Enters into Licensing Agreement with Medicines Patent Pool 204
XL-protein Enters into Licensing Agreement with MSD Animal Health 205
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 206
EnWave Enters into Licensing Agreement with Merck 208
Zymeworks Extends Licensing Agreement with Merck 209
Merck Enters into Licensing Agreement with NewLink Genetics 210
Euroscreen Enters into Licensing Agreement with Merck 212
Sun Pharma Enters into Licensing Agreement with Merck 213
Kyorin Pharma Enters into Licensing Agreement with Merck 215
Bionomics Enters into Licensing Agreement with Merck for BNC375 216
Chimerix Terminates Licensing Agreement with Merck for CMX-157 218
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 219
Gulf Pharma Enters into Licensing Agreement with MSD 221
NanoBio Enters Into Licensing Agreement With Merck 222
Nuevolution Enters Into Licensing Agreement With Merck 223
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 224
Merck Expands Licensing Agreement with Ablynx 226
Polyplus-transfection Enters Into Licensing Agreement With Merck 228
AstraZeneca Enters Into Licensing Agreement With Merck For MK-1775 229
Depomed Expands Licensing Agreement With Merck For Metformin Patents 231
Bionomics Extends Licensing Agreement with Merck 232
Merck Enters Into Licensing Agreement With Lupin 234
Xencor Enters Into Licensing Agreement With Merck 236
Merck Terminates Licensing Agreement With Scynexis For MK-3118 237
Cerecor Enters Into Licensing Agreement With Merck For MK-0657 239
Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 240
Hawaii Biotech Enters Into Licensing Agreement With Merck For West Nile Vaccine Technology 242
Acerta Pharma Enters into Licensing Agreement with Merck Sharp & Dohme 243
Cubist Pharma Enters Into Licensing Agreement With Astellas Pharma For Ceftolozane 244
Microbiotix Enters Into Licensing Agreement With Merck For MBX-700 And MBX-701 246
Merck Enters Into Licensing Agreement With GE Healthcare For Flutemetamol 248
Helix BioPharma And Merck Terminate Option For Licensing Agreement For Topical Interferon Alpha-2b 249
Netherlands Translational Research Center Enters Into Licensing Agreement With Merck 250
Theravance Enters Into Licensing Agreement With Merck For Cardiovascular Therapeutic Candidates 251
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 252
Delphi Genetics Enters Into Licensing Agreement With Merck For StabyExpress Technology 254
Merck Terminates Licensing Agreement with Cardiome Pharma for Vernakalant 255
MultiVir Enters into Licensing Agreement with Merck Sharp & Dohme 257
Merck Enters Into Licensing Agreement With Yamasa For EFdA 258
Merck Enters Into Licensing Agreement With Chimerix For CMX157 259
R-Pharm Enters Into Licensing Agreement With Merck For Narlaprevir 261
Ambrx Enters Into Licensing Agreement With Merck For Site Specific Protein Medicinal Chemistry Technology 262
Tesaro Enters Into Licensing Agreement With Merck Sharp & Dohme For Cancer Drug 264
Merck Enters Into Licensing Agreement With Numerate For In Silico Drug Design Technology 265
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 266
Exelixis Enters Into Licensing Agreement With Merck For PI3K-delta 267
Mochida Pharma Enters Into Licensing Agreement With Merck 269
Bend Research Enters Into Licensing Agreement With Merck 270
Hawaii Biotech Enters Into Licensing Agreement With Merck 271
Merck Terminates Licensing Agreement With Ligand Pharma 272
Merck Terminates Licensing Agreement With Japan Tobacco For JTT-305 273
Merck Enters Into Licensing Agreement With FKD Therapies 274
Addex Pharma Terminates Licensing Agreement With Merck For mGluR4 PAM 275
Zymeworks Enters Into Licensing Agreement With Merck 276
AbD Serotec Amends Licensing Agreement With Merck 277
Addex Pharma Terminates Licensing Agreement With Merck For ADX63365 278
MSD Enters Into Licensing Agreement With Astellas US For vernakalant 279
Hanwha Chemical Enters Into Licensing Agreement With Merck For HD203 280
Intercell Terminates Its Licensing Agreement With Merck For V710 282
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 283
Portola Pharma Terminates Licensing Agreement With Merck For Betrixaban 284
Cardiovascular BioTherapeutics Enters Into Licensing Agreement With An Affiliate Of Merck 285
Cortex Pharma Terminates Licensing Agreement With Organon BioSciences 287
Merck Enters Into Licensing Agreement With Janssen For Caeylx 288
Horizon Discovery Enters Into Licensing Agreement With Merck & Co 289
Merck Enters Into Licensing Agreement With ElexoPharm 290
Ariad Pharma Amends Its Collaboration Agreement With Merck 291
The University of Massachusetts Medical Enters Into Licensing Agreement With Merck 293
GTx Terminates Worldwide Licensing Agreement With Merck 295
Anacor Pharma Terminates Licensing Agreement With Merck 296
Equity Offering 297
Bionomics Raises USD9 Million in Private Placement of Shares 297
OpGen Raises USD5 Million in Private Placement of Shares 298
BeiGene Raises USD97.4 Million in Private Placement of Series A-2 Preferred Stock 300
Moderna Therapeutics Raises USD50 Million in Private Placement of Shares 301
VirtualScopics Completes First Tranche Of Private Placement Of Shares For US$3 Million 302
Debt Offering 304
Merck Completes Public Offering of Notes Due 2020 for USD700 Million 304
Merck Completes Public Offering of Notes Due 2025 for USD2.5 Billion 306
Merck Completes Public Offering of Notes Due 2017 for USD300 Million 308
Merck Completes Public Offering of Notes Due 2045 for USD2 Billion 310
Merck Completes Public Offering of Notes Due 2020 for USD1.25 Billion 312
Merck Completes Public Offering of Notes Due 2022 for USD1.25 Billion 314
Merck Raises USD1.25 Billion in Public Offering of 1.875% Notes Due 2026 316
Merck Raises USD625 Million in Public Offering of 2.5% Notes Due 2034 318
Merck Raises USD1.25 Billion in Public Offering of 1.125% Notes Due 2021 320
Cubist Pharma Completes Private Placement Of Notes Due 2020 For US$450 Million 322
Cubist Pharma Completes Private Placement Of Notes Due 2018 For US$350 Million 323
Merck Completes Public Offering Of Notes Due 2016 For US$500 Million 324
Merck Completes Public Offering Of Notes Due 2016 For US$1 Billion 326
Merck Completes Public Offering Of Notes Due 2018 For US$1 Billion 328
Merck Completes Public Offering Of Notes Due 2023 For US$1.75 Billion 330
Merck Completes Public Offering Of Notes Due 2043 For US$1.25 Billion 332
Merck Completes Public Offering Of Floating Notes Due 2018 For US$1 Billion 334
Merck Completes Public Offering Of Notes Due 2042 For US$500 Million 336
Merck Completes Public Offering Of 1.1% Notes Due 2018 For US$1 Billion 338
Merck Completes Public Offering Of Notes Due 2022 For US$1 Billion 340
Merck Completes Public Offering Of 2.250% Senior Notes Due 2016 For US$850 Million 342
Merck Completes Public Offering Of 3.875% Senior Notes Due 2021 For US$1,150 Million 344
Cubist Pharma Completes Private Placement Of Convertible Senior Notes Due 2017 For US$450 Million 346
Asset Transactions 348
ANI Pharma Acquires Two NDAs from Merck Sharp & Dohme for USD75 Million 348
Piramal Enterprises Acquires Five OTC Brands from Organon India and MSD for USD14 Million 349
Mundipharma Ophthalmology Acquires Glaucoma Products Portfolio from Merck 350
Merial to Acquire Manufacturing Facility from Merck 351
Merck Withdraws Sale of Consumer Healthcare Business 352
Santen Pharma Acquires Remaining Portfolio of Ophthalmology Products from Merck for USD50 Million 354
Bayer Acquires Consumer Healthcare Business of Merck for USD14.2 Billion 356
AstraZeneca Exercises Option to Acquire Interest in Proton Pump Inhibitor Products from Merck 358
KBI Biopharma To Acquire Biologics Operations Of Merck 360
Amphastar Pharmaceuticals Acquires API manufacturing business of Merck 361
Oak Pharma Acquires Tafluprost Business from Merck 362
Aspen Acquires Portfolio of Drugs from Merck for USD600 Million 363
Forest Labs To Acquire US Marketing Rights To Saphris From Merck Sharp & Dohme For US$240 Million 365
CCS Healthcare To Acquire Propyless From Merck Sharp & Dohme 367
Aspen Acquires Active Pharmaceutical Ingredients Business From Merck 368
Cerecor Acquires Rights To COMT Inhibitors From Merck 369
Kyorin Acquires Production Facility from MSD 370
Pop Test Cortisol Acquires Org34517 From Merck 371
Merck Plans To Sell Miami Lakes Manufacturing Plant 372
AstraZeneca Completes Acquisition Of Rights To Certain Drugs From Merck 373
Reckitt Benckiser Acquires Rights To Narcotic Addition Treatments From Merck 374
Acquisition 375
Merck Acquires IOmet Pharma 375
Merck Acquires cCAM Biotherapeutics 376
Merck Acquires Cubist Pharma for USD9.5 Billion 378
Merck Acquires OncoEthix for USD375 Million 381
Merck Completes Acquisition of Idenix Pharma for USD3.85 Billion in Tender Offer 382
Alnylam Pharma Completes Acquisition Of Sirna Therapeutics From Merck 384
Cubist Pharma Terminates Option To Acquire Adynxx, Pain Treatment Maker 386
Akorn Acquires Inspire Pharma From Merck For US$53 Million 388
Cubist Pharma Completes Acquisition Of Optimer Pharma For Up To US$801 Million 390
Cubist Pharma Completes Acquisition Of Trius Therapeutics For Up To US$818 Million In A Tender Offer 392
Telerx Acquires Sentrx Safety Solutions, Pharmacovigilance Outsourcing Company 394
Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 395
Merck Plans To Acquire Micro Labs, Maker Of Generic Drugs 397
Cubist Pharma Completes Acquisition Of Adolor For US$415 Million 398
Johnson & Johnson Acquires Johnson & Johnson Merck Consumer Pharma From Merck Sharp & Dohme For US$175 Million 400
Nuvisan Acquires Essex Pharma Development From Merck 401
Merck Completes Acquisition Of Inspire Pharma 403
Fujifilm Completes Acquisition Of MSD Biologics 406
Fujifilm Completes Acquisition Of Diosynth 408
Merck Terminates Sale Of Its Stake In Organon BioSciences 409
Merck Acquires SmartCells 411
PerkinElmer Completes Acquisition Of VisEn Medical 413
Laboratorios Farmaceuticos Acquires Frosst Iberica From Merck & Co 415
Merck & Co Completes Acquisition Of Avecia Biologics 416
Merck & Co., Inc. - Key Competitors 417
Key Employees 418
Locations And Subsidiaries 420
Head Office 420
Other Locations & Subsidiaries 420
Appendix 447
Methodology 447
About GlobalData 447
Contact Us 447
Disclaimer 447
List of Tables
Merck & Co., Inc., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 17
Merck & Co., Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 18
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 19
Merck & Co., Inc., Deals By Therapy Area, 2010 to YTD 2016 20
Merck & Co., Inc., Medical Devices Deals, 2010 to YTD 2016 22
Merck & Co., Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 23
Hypermarcas To Sell Rights To Manufacture Medicines To MSD Brazil Investments For US$31 Million 42
Merck Reacquires Cherokee Chemical Manufacturing Plant From PRWT Services 43
Merck Sharp & Dohme Acquires Dengue Fever Vaccine Research Unit From Hawaii Biotech 44
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 45
RaNA Therapeutics Raises USD55 Million in series B Financing 47
Gladius Pharma Raises USD3.3 Million in Series A Financing 49
NGM Biopharma Raises USD106 Million in Series E Financing 50
EnGene Raises USD11 Million in Series B Venture Financing 51
OsteoQC Raises Funds in Venture Financing 52
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 53
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 54
Aviir Raises US$20 Million In Venture Financing 56
cCAM Biotherapeutics Raises US$6 Million In Series A Financing 58
Aviir Secures US$10 Million In Venture Financing 59
High Throughput Genomics Secures US$0.5 Million In Second Closing Of Series D Venture Round 61
BeiGene Receives Investment From Merck Sharp & Dohme 63
SmartCells Raises US$4.1 Million In Series D Preferred Stock Financing 64
TPP Global Development Raises US$14.2 Million In Venture Financing 65
CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test 66
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 67
Merck and Sanofi Pasteur Plans to Terminate Joint Venture 68
Myriad Genetics Enters into Research Agreement with Tesaro and Merck 69
Daiichi Sankyo Enters into Co-Marketing Agreement with Merck 70
Sun Pharma Terminates Joint Venture with MSD Pharma 71
ImmunoGen Enters into Research Agreement with Merck 72
Merck Enters into Agreement with AbCellera Biologics 73
Affimed Enters into Research Agreement with Merck 74
BioLineRx Enters into Agreement with Merck 75
Quartet Medicine Enters into Agreement with Merck 76
Complix Enters into Agreement with Merck 77
Eli Lilly Enters into Agreement with Merck 78
Merck Enters into Agreement with Akeso Biopharma 79
Amgen and Merck Enter into Agreement 80
Viralytics Enters into Agreement with Merck 81
GlaxoSmithKline Partners with Merck 82
Synthace Enters into Agreement with Merck 83
MacroGenics Enters into Agreement with Merck 84
Incyte Extends Partnership with Merck 85
Merck Enters into Agreement with OBI Pharma 86
Merck Enters into Agreement with DNAtrix 87
Merck Enters into Research Agreement with University of Texas MD Anderson Cancer Center 88
Immune Design Enters into Clinical Collaboration Agreement with Merck 89
Laboratorios Farmaceuticos Rovi Enters into Co-Marketing Agreement with Merck Sharp & Dohme for Orvatez 90
Merck Sharp & Dohme Expands its Agreement with NanoString Technologies 91
PeptiDream Enters into Peptide Discovery Agreement with Merck 92
Organovo Enters into Research Agreement with Merck Sharp & Dohme 93
Astellas Pharma to Enter into Agreement with MSD 94
Syndax Pharma Enters into Agreement with Merck 95
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 96
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 97
Laboratoires Merck Sharp Terminates Joint Venture with Simcere Pharma 99
Merck Expands Agreement with Eli Lilly 100
Kyorin Pharma Enters into Co-Marketing Agreement with MSD 101
Bind Therapeutics Enters into R&D Agreement with Merck 102
Advaxis Enters into Agreement with Merck 103
Endocyte Terminates Co-Development Agreement with Merck for vintafolide 104
Bayer Enters Into Agreement With Merck For Soluble Guanylate Cyclase Modulators 105
Ferring Pharma And Merck Enter Into Agreement With World Health Organization For Anti-Bleeding Drug 107
Merck Enters Into Co-Development Agreement With Samsung Bioepis For MK-1293 109
Dako Enters Into Co-Development Agreement With Merck 110
Astellas Pharma Enters Into Co-Promotion Agreement With MSD For Ipragliflozin 111
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 113
Optimer Pharma Extends Co-Promotion Agreement With Cubist Pharma For Dificid 115
Abide Therapeutics Enters Into Co-Development Agreement With Merck 116
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 117
Ra Pharma Enters Into Agreement With Merck To Develop Cyclomimetics 119
Merck And Samsung Bioepis Enter Biosimilars Development Agreement 120
Lycera Enters Into Research Agreement With Merck To Develop Novel Treatments For Autoimmune Diseases 121
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 122
Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs 123
ActoGeniX Enters Into Research Agreement With Merck 124
TPP Global Development Enters Into Agreement With Sprint Biosciences To Develop Choline Kinase Inhibitors 125
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 126
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 127
Redbiotec Extends Drug Discovery Agreement With Merck 129
Merck Forms Joint Venture With Supera Farma Laboratorios 130
MSD Enters Into Distribution Agreement With Julphar 131
AstraZeneca Amends Co-Development Agreement With Merck For Nexium And Prilosec 132
Fundacion Medina Enters Into Research Agreement With Cubist Pharma 134
Chongqing Zhifei Biological Products Extends Co-Marketing Agreement With Merck For RotaTeq 135
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 136
Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 137
MSD India Plans Co-Marketing Agreement For Diabetes Drugs 139
Takeda Pharma International Terminates Co-Promotion Agreement With Merck For Daxas 140
Ezose Sciences Enters Into Co-Development Agreement With Merck 141
Vaccine & Gene Therapy Institute Enters Research Agreement With Merck 142
Redbiotec Enters Into Drug Discovery Agreement With Merck 143
Merck Enters Into Co-Development Agreement With Beijing Genomics Institute 144
Merck Enters Into Co-Development Agreement With Serum Institute of India 145
Merck Extends Co-Promotion Agreement With Roche For VICTRELIS 147
Merck Enters Into Co-Promotion Agreement With Daewoong Pharma For Vytorin 149
MSD Enters Into Co-Marketing Agreement With Taiho Pharma For Vorinostat 150
MSD In India Enters Into Co-Marketing Agreement With Sun Pharma 152
Merck Amends Distribution Agreement With Johnson & Johnson 154
Optimer Pharma Enters Into Co-Promotion Agreement With Cubist Pharma 156
TPP Global Development Enters Into Agreement With University of Aberdeen 158
ARIAD Announces Co-Promotion Agreement With Merck 159
Lycera Enters Into Research Agreement With Merck 160
Merck & Co. Terminates Co-Development Agreement With Galapagos For Inflammatory Diseases 162
Merck & Co. Terminates Co-Development Agreement With Galapagos 163
Merck Enters Into An Agreement With PAREXEL International 164
Ranbaxy Labs Terminates Co-Development Agreement With Merck 165
H Lundbeck Enters Into Collaboration With Merck For SYCREST 166
BioRelix Enters Into Research Collaboration With A Subsidiary Of Merck 168
NicOx Expands Research Collaboration With Merck & Co 169
Karo Bio Terminates Its Collaboration With Merck & Co For MK-6913 170
Adcock Ingram Holdings Expands Its Distribution Agreement With Merck 171
TPP Global Development Enters Into Collaboration Agreement With The University Of Edinburgh 172
Alectos Therapeutics Enters Into Research Collaboration With Merck & Co 173
Merck & Co Enters Into Co-Marketing Agreement With Sinopharm Group 174
Merck Sharp & Dohme Signs Letter Of Intent With Sinopharm Group 175
Adcock Ingram Enters Into Co-Promotion And Distribution Agreement With Merck 176
Pharmasset Plans Co-Development Agreement For PSI-7977 178
National Taiwan University Hospital Enters Into Collaboration With Merck Sharp 180
Nycomed Enters Into Co-Marketing Agreement With Merck 181
Nycomed Enters Into Co-Promotion Agreement With Merck 183
Laboratorios Farmaceuticos Enters Into Co-Marketing Agreement With Merck & Co 185
University of Pittsburgh Partners With Battelle, IBM And Merck 186
Banyu Pharma Enters Into Co-Promotion Agreement With Santen Pharma 188
Evotec Extends Research Agreement With Cubist Pharma 189
Eli Lilly, Merck And Pfizer Form Joint Venture 190
AnaptysBio Enters Into Collaboration Agreement With Merck 192
Envoy Therapeutics Enters Into Research Agreement With Merck & Co. 193
Merck Enters into Licensing Agreement with Harvard University 194
Merck Enters into Licensing Agreement with AureoGen Biosciences 195
Merck Enters into Licensing Agreement with Cancer Research Technology 196
Adimab Enters into Licensing Agreement with Merck 197
Merck Enters into Licensing Agreement with Selvita 198
Merck Enters into Licensing Agreement with Codexis for CodeEvolver Platform Technology 199
Allergan Enters into Licensing Agreement with Merck 201
Merck Extends Licensing Agreement with Agenus 202
Arvinas Enters into Licensing Agreement with Merck 203
Merck Enters into Licensing Agreement with Medicines Patent Pool 204
XL-protein Enters into Licensing Agreement with MSD Animal Health 205
Moderna Therapeutics Amends Terms of Licensing Agreement with Merck 206
EnWave Enters into Licensing Agreement with Merck 208
Zymeworks Extends Licensing Agreement with Merck 209
Merck Enters into Licensing Agreement with NewLink Genetics 210
Euroscreen Enters into Licensing Agreement with Merck 212
Sun Pharma Enters into Licensing Agreement with Merck 213
Kyorin Pharma Enters into Licensing Agreement with Merck 215
Bionomics Enters into Licensing Agreement with Merck for BNC375 216
Chimerix Terminates Licensing Agreement with Merck for CMX-157 218
Agenus Enters into Licensing Agreement with Merck for Checkpoint Antibody-based Cancer Immunotherapies 219
Gulf Pharma Enters into Licensing Agreement with MSD 221
NanoBio Enters Into Licensing Agreement With Merck 222
Nuevolution Enters Into Licensing Agreement With Merck 223
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 224
Merck Expands Licensing Agreement with Ablynx 226
Polyplus-transfection Enters Into
